| Prev Close | 3.78 |
| Day Low/High | 3.85 / 4.08 |
| 52 Wk Low/High | 3.48 / 12.83 |
Sangamo Therapeutics, Inc. (SGMO)
4.02
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 146.69B |
| Market Cap | 554.48M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
This Is Great Action for Stock Pickers Right Now
Stick to themes like biotechnology, SPACs, EV batteries, and others.
I'm Staying Very Watchful of Overall Market Conditions
I'm concerned about breadth, and if we start seeing 3 to 1 negative breadth then I'll be very concerned.
There's No Outside Force Having Any Impact on This Market Right Now
The hardest thing to do is to stick with the momentum and not give in to the temptation to sell prematurely.
This Is Narrower Action and That's a Warning Sign
The action does feel a little tired and more forced but there still isn't any real shift in the price action.
Sangamo Therapeutics Shows Promise
Let's check out the charts of SGMO and come up with a trading strategy.
The Only Kind of Trading That Works in This Sort of Market
Defense is more important than offense right now.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Market Action Is Quite Random
The indices moved into positive territory and now the action has cooled off.
10 Speculative Stock Plays in the Biotech Sector
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
I Have My Eye on This Warren Buffett Stock Amid the Choppy Action
Market players are more skeptical of the quick moves on U.S.-China trade news.
5 Stocks on My Radar During a Quiet Day
Sometimes dull action like this can be good for trading.
Here's How I Would Handle Speculative Sangamo Therapeutics
Let's take a look at the charts and indicators.
Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019
From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.
Coffee Acquisition or Not, Coca-Cola Doesn't Have Much Fizz
Despite $5.1 billion deal for Costa, I'm not slurping any KO up.
A Lesson to Learn From Thursday's Market Action
You don't have to be Sigmund Freud to understand the psychology here.
Salesforce Remains a 'Go to' Name for Big Cap Momentum Players
I expect CRM to regain its footing quickly and challenge highs again soon.
HPE: Surpassing Expectations, Raising Guidance Incrementally
If estimates continue to come up there will be institutional interest in the stock.
Strength in Growth Names Is Giving the Market a More Upbeat Feel
Apple in particular is helping the bullish cause.
Traders Are Still Finding Plenty of Stocks That They Want to Buy
Sentiment is very positive, regardless of what the indices may say.
3 Biotech Best Bets From the 'Stock Picker of the Year'
In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.
Many Names on My Radar
There is no question that we are becoming extended and ripe for some profit taking.
The Market Is Finally Rewarding Stock Picking
The game plan is to spot the charts that have more room to run.
Markets Recovering From Latest Trump Tweetstorm
Wall Street discounting talk of bombing Syria from president.
Biotechs Take the Lead This Morning
Whether this market continues to bounce is going to depend a great degree on the FAANG names.
2 Biotech Stocks to Consider
Many stocks are already at support levels and are offering opportunities to start some positions.
Why Gun-Shy Market Bulls Can't Pull the Trigger Like They Used To
4 stocks on my shopping list for when conditions improve.
Sound Familiar? Dovish Fed Talk Induces Stock Reversal
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Biotech Heats Up as Fear of Missing Out Returns
It's hard to believe the bounce will continue to run in V-shaped fashion.
